Skip to content

Drug interactions

Fedratinib + Liposomal doxorubicin

Severity: Moderate

Fedratinib and Liposomal doxorubicin: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Fedratinib inhibits CYP3A4 and CYP2D6 and may increase doxorubicin exposure. This could increase myelosuppression and cardiotoxicity, which are both already concerns with fedratinib therapy.

What this interaction means in plain words

Fedratinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Fedratinib belongs to Oncology; Liposomal doxorubicin belongs to Oncology.

Evidence level: Low

Why it happens

Fedratinib inhibits CYP3A4 and CYP2D6, reducing doxorubicin metabolism.

What to do

Monitor blood counts and cardiac function, and reduce the doxorubicin dose if toxicity develops.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Fedratinib and Liposomal doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Fedratinib with Liposomal doxorubicin?

MediHelp rates the interaction as moderate. Fedratinib and Liposomal doxorubicin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Fedratinib inhibits CYP3A4 and CYP2D6 and may increase doxorubicin exposure. This could increase myelosuppression and cardiotoxicity, which are both already concerns with fedratinib therapy.

How serious is the interaction between Fedratinib and Liposomal doxorubicin?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function, and reduce the doxorubicin dose if toxicity develops.

What other medicines interact with Liposomal doxorubicin?

MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in